

## APC anti-human CD4 Antibody

<b>Catalog# / Size</b>	317415 / 25 tests 317416 / 100 tests
<b>Clone</b>	OKT4
<b>Regulatory Status</b>	RUO
<b>Workshop</b>	HCDM listed
<b>Other Names</b>	T4
<b>Isotype</b>	Mouse IgG2b, κ
<b>Description</b>	CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

### Product Details

<b>Verified Reactivity</b>	Human, Cynomolgus, Rhesus
<b>Reported Reactivity</b>	Chimpanzee
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Immunogen</b>	Human peripheral T cells
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).  In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4. <sup>9</sup>

### Application References

1. Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Reinherz EL, *et al.* 1979. *Proc. Natl. Acad. Sci.* 76:4061.
3. Kmiecik M, *et al.* 2009. *J. Transl. Med.* 7:89. (FC) [PubMed](#)
4. Cicin-Sain L, *et al.* 2010. *J. Immunol.* 184:6739. [PubMed](#)
5. Rosenzweig M, *et al.* 2001. *J. Med. Primatol.* 30:36.

6. Linder J, *et al.* 1987. *Am. J. Pathol.* 127:1.
7. Boche D, *et al.* 1999. *J. Neurovirol.* 5:232. (IHC)
8. Reinherz EL, *et al.* 1979. *Proc. Natl. Acad. Sci. USA.* 76:4061. (Immunogen)
9. Lederman S, *et al.* 1991. *Mol Immunol.* 28:1171-81.

## Product Citations

1. Carre C, *et al.* 2021. *iScience.* 24:102970. [PubMed](#)
2. Wang T, *et al.* 2022. *Front Immunol.* 13:954121. [PubMed](#)
3. Soday L, *et al.* 2021. *Frontiers in Immunology.* 12:600056. [PubMed](#)
4. Mete B, *et al.* 2022. *Life Sci Alliance.* 5: [PubMed](#)
5. Claiborne DT, *et al.* 2019. *PLoS Pathog.* 15:e1007981. [PubMed](#)
6. Uhlenbrock F, *et al.* 2014. *J Immunol.* 193:1654. [PubMed](#)
7. Zhu ZY, *et al.* 2022. *Front Immunol.* 12:781087. [PubMed](#)
8. Azizi E *et al.* 2018. *Cell.* 174(5):1293-1308 e36. [PubMed](#)
9. Want MY, *et al.* 2019. *Oncoimmunology.* 8:e1586042. [PubMed](#)
10. Sun J, *et al.* 2018. *Scand J Immunol.* 88:e12674. [PubMed](#)
11. Ahmed R *et al.* 2019. *Cell.* 177(6):1583-1599. [PubMed](#)
12. Saadati S, *et al.* 2020. *Avicenna J Med Biotechnol.* 0.591666667. [PubMed](#)
13. Wang Z, *et al.* 2021. *Cell Mol Immunol.* 18:2188. [PubMed](#)
14. Ma C, *et al.* 2021. *Signal Transduct Target Ther.* 6:353. [PubMed](#)
15. Dushyanthen S, *et al.* 2017. *Nat Commun.* 10.1038/s41467-017-00728-9. [PubMed](#)
16. Li N, *et al.* 2021. *STAR Protoc.* 2:100942. [PubMed](#)
17. Bellini N, *et al.* 2022. *iScience.* 25:105234. [PubMed](#)
18. Altman K 2006. *J Immunol.* 177:1721. [PubMed](#)
19. Acerbi E, *et al.* 2016. *Sci Rep.* 6:23128. [PubMed](#)
20. Beatson RE, *et al.* 2021. *Cell Rep Med.* 2:100473. [PubMed](#)
21. Alsaleh G, *et al.* 2020. *Elife.* 9: [PubMed](#)
22. Jiang H, *et al.* 2021. *Oncoimmunology.* 10:1943180. [PubMed](#)
23. Arif S, *et al.* 2020. *Diabetologia.* 63(6):1186-1198. [PubMed](#)
24. Narsale A, Moya R, Robertson H 2016. *Data Brief.* 8: 1348-51. [PubMed](#)
25. Sugita S, *et al.* 2016. *Stem Cell Reports.* 7:619-634. [PubMed](#)
26. Wang A, *et al.* 2020. *Front Immunol.* 1.213194444. [PubMed](#)
27. Zhang J, *et al.* 2022. *Nature.* 609:369. [PubMed](#)
28. Berezhnoy A, *et al.* 2020. *Cell Rep Med.* 1:100163. [PubMed](#)
29. Johnson A, *et al.* 2016. *mSphere.* 1: e00288-16. [PubMed](#)
30. Bigler M, *et al.* 2015. *PLoS One.* 10: 0145635. [PubMed](#)
31. Kim K, *et al.* 2019. *Nat Microbiol.* 1.586111111. [PubMed](#)
32. Jafari M, *et al.* 2014. *J Virol.* 88:5062. [PubMed](#)
33. Frencher J, *et al.* 2014. *J Leukoc Biol.* 96:957. [PubMed](#)
34. Li N, *et al.* 2021. *Cell Rep Med.* 2:100297. [PubMed](#)
35. Dahal S, *et al.* 2022. *Retrovirology.* 19:18. [PubMed](#)
36. Li N, *et al.* 2020. *Oncoimmunology.* 9:1824643. [PubMed](#)
37. Bossini-Castillo L, *et al.* 2022. *Cell Genom.* 2:None. [PubMed](#)
38. Roy S, *et al.* 2021. *Nat Commun.* 12:3182. [PubMed](#)
39. Ledderose C, *et al.* 2021. *J Leukoc Biol.* 109:497. [PubMed](#)
40. Cirelli KM *et al.* 2019. *Cell.* 177(5):1153-1171. [PubMed](#)
41. Dupont L, *et al.* 2021. *Cell Host Microbe.* 29(5):792-805.e6. [PubMed](#)
42. Mishra A, *et al.* 2021. *Cell.* 184(13):3394-3409.e20. [PubMed](#)
43. Comte D, *et al.* 2016. *Proc Natl Acad Sci U S A.* 113: 9321 - 9326. [PubMed](#)
44. Reyes M, *et al.* 2021. *Sci Transl Med.* 13: [PubMed](#)
45. Mujib S, *et al.* 2017. *JCI Insight.* 2:e93687. [PubMed](#)
46. Su Y, *et al.* 2020. *Cell.* 1479:183. [PubMed](#)
47. Sashihara J, *et al.* 2011. *PLoS One.* 6:e1002308. [PubMed](#)
48. Clayton KL, *et al.* 2021. *Cell Host Microbe.* 29(3):435-447.e9. [PubMed](#)
49. Siedlik J, *et al.* 2017. *J Immunol Methods.* 10.1016/j.jim.2017.03.017. [PubMed](#)
50. Okutani Y, *et al.* 2022. *Tissue Eng Part A.* 28:94. [PubMed](#)
51. Kang HM, *et al.* 2018. *Nat Biotechnol.* 36:89. [PubMed](#)
52. Dotson A, *et al.* 2013. *Clin Immunol.* 148:149. [PubMed](#)

## RRID

AB\_571944 (BioLegend Cat. No. 317415)  
 AB\_571945 (BioLegend Cat. No. 317416)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, type I transmembrane glycoprotein, 55 kD
<b>Distribution</b>	T cell subset, majority of thymocytes, monocytes/macrophages
<b>Function</b>	MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
<b>Ligand/Receptor</b>	MHC class II molecules, HIV gp120, IL-16
<b>Cell Type</b>	Macrophages, Monocytes, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Immunology

**Molecular Family** CD Molecules

**Antigen References** 1. Center D, *et al.* 1996. *Immunol. Today* 17:476.  
2. Gaubin M, *et al.* 1996. *Eur. J. Clin. Chem. Clin. Biochem.* 34:723.

**Gene ID** [920](#)


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Brilliant Violet 650™ anti-human CD4, Purified anti-human CD4, Biotin anti-human CD4, FITC anti-human CD4, PE anti-human CD4, PE/Cyanine5 anti-human CD4, PE/Cyanine7 anti-human CD4, APC anti-human CD4, APC/Cyanine7 anti-human CD4, Alexa Fluor® 488 anti-human CD4, Alexa Fluor® 647 anti-human CD4, Alexa Fluor® 700 anti-human CD4, Pacific Blue™ anti-human CD4, PerCP/Cyanine5.5 anti-human CD4, PerCP anti-human CD4, Brilliant Violet 421™ anti-human CD4, Brilliant Violet 605™ anti-human CD4, Brilliant Violet 711™ anti-human CD4, Brilliant Violet 785™ anti-human CD4, Brilliant Violet 510™ anti-human CD4, Brilliant Violet 570™ anti-human CD4, PE/Dazzle™ 594 anti-human CD4, TotalSeq™-A0922 anti-human CD4, Ultra-LEAF™ Purified anti-human CD4

## Product Data



Human peripheral blood lymphocytes stained with OKT4 APC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587